Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients.
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) / Di Giambenedetto, Simona; Fabbiani, Massimiliano; Quiros Roldan, Eugenia; Latini, Alessandra; D'Ettorre, Gabriella; Antinori, Andrea; Castagna, Antonella; Orofino, Giancarlo; Francisci, Daniela; Chinello, Pierangelo; Madeddu, Giordano; Grima, Pierfrancesco; Rusconi, Stefano; Di Pietro, Massimo; Mondi, Annalisa; Ciccarelli, Nicoletta; Borghetti, Alberto; Focà, Emanuele; Colafigli, Manuela; De Luca, Andrea; Cauda, Roberto. - ELETTRONICO. - (2017), p. dkw557.
Titolo: | Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) |
Autori: | |
Data di pubblicazione: | 2017 |
Rivista: | |
Citazione: | Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) / Di Giambenedetto, Simona; Fabbiani, Massimiliano; Quiros Roldan, Eugenia; Latini, Alessandra; D'Ettorre, Gabriella; Antinori, Andrea; Castagna, Antonella; Orofino, Giancarlo; Francisci, Daniela; Chinello, Pierangelo; Madeddu, Giordano; Grima, Pierfrancesco; Rusconi, Stefano; Di Pietro, Massimo; Mondi, Annalisa; Ciccarelli, Nicoletta; Borghetti, Alberto; Focà, Emanuele; Colafigli, Manuela; De Luca, Andrea; Cauda, Roberto. - ELETTRONICO. - (2017), p. dkw557. |
Abstract: | Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. |
Handle: | http://hdl.handle.net/11379/487424 |
Appare nelle tipologie: | 1.1 Articolo in rivista |